ADDITIONAL USE OF TRIMETAZIDINE IN PATIENTS WITH CHRONIC HEART FAILURE. A META-ANALYSIS

1. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res 2009;81:412–9. 2. Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 1996;28:341–50.

2. Kantor PF , Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580–8.

3. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coronary Artery Dis 2003;14:171–9.

4. Ruixing Y , Wenwu L, Al-Ghazali R. Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion. Transl Res 2007;149:152–60.

5. Williams FM, T anda K, Kus M, Williams TJ. T rimetazidine inhibits neutrophil accumulation after myocardial-ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993;22:828–33.

6. Di Napoli P , Chierchia S, Taccardi AA, et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide-Biol Ch 2007;16:228–36.

7. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001;22:2164–70.

8. Belardinelli R, Solenghi M, Volpe L, Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J 2007;28:1102–8.

9. Belardinelli R, Cianci G, Gigli M, Mazzanti M, Lacalaprice F . Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol 2008;51:611–5.

10. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990;11:207–12.

11. Cera M, Salerno A, Fragasso G, et al. Beneficial electrophysiological effects of trimetazidine in patients with postischemic chronic heart failure. J Cardiovasc Pharmacol Ther 2010;15:24–30.

12. Di Napoli P , Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91:161–5.

13. Di Napoli P , Di Giovanni P , Gaeta MA, D’Apolito G, Barsotti A. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J 2007;154:602.e1–5.

14. El-Kady T , El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005;5:271–8.

15. Fragasso G, Palloshi A, Puccetti P , et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor , in patients with heart failure. J Am Coll Cardiol 2006;48:992–8.

16. Gunes Y , Guntekin U, Tuncer M, Sahin M. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels 2009;24:277–82.

17. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003;2:16.

18. Sisakian H, Torgomyan A, Barkhudaryan A, Sisakian H, Torgomyan A, Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic car- diomyopathy. Acta Cardiol 2007;62:493–9.

19. Thrainsdottir IS, von Bibra H, Malmberg K, Ryden L. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol 2004;44:101–8. 21. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator , has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008;118:1250–8.

20. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25:1814–21.

21. Zemljic G, Bunc M, Vrtovec B. Trimetazidine shortens QTc interval in patients with ischemic heart failure. J Cardiovasc Pharmacol Ther 2010;15:31–6.

22. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions — Potential for pharmacological interventions. Cardiovasc Res 1997;33:243–57.

23. Katz AM. Is the failing heart energy depleted? Cardiol Clin 1998;16:633–44.

24. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004;25:634–41.

25. Deleiris J, Boucher F . Rationale for trimetazidine administration in myocardial-ischemia reperfusion syndrome. Eur Heart J 1993;14:34–40.

26. Levin ER, Gardner DG, Samson WK. Mechanisms of disease - Natriuretic peptides. New Engl J Med 1998;339:321–8.

27. Kiyosue T , Nakamura S, Arita M. Effects of trimetazidine on action potentials and membrane currents of guinea-pig ventricular myocytes. J Mol Cell Cardiol 1986;18:1301–11.

28. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002;91:988–98.

29. Genissel P , Chodjania Y , Demolis JL, Ragueneau I, Jaillon P . Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. Eur J Drug Metab Pharmacokinet 2004;29:61–8.